APAbhilash Patra

Abhilash Patra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abhilash Patra has a total of 69 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Health-related quality of life (HRQoL) of women with breast cancer undergoing treatment in a tertiary care centre in India

    by Abhilash Patra, Shona Nag, Shriniwas Subhash Kulkarni, Rebecca DeSouza, Hira B. Pant, Varun Agiwal, A. Y. Nirupama, G. V. S. Murthy

    Introduction: Breast cancer in India accounts for 178361 of all cancers (Globocan 2020 report). Treatment causes financial, social, and psychological stress, impacting patients’ quality of life (QoL). Multiple studies have reported QoL among survivors, however few studies focused on patients undergoing treatment in India. Hence, the present study aimed to measure the QoL and its influencing factors associated with breast cancer undergoing various treatments in the oncology department of a tertiary care hospital in India. Methods: A hospital-based cross-sectional study (Nov 2022 - Jan 2023) used a semi-structured questionnaire on participants’ sociodemographic and clinical characteristics. The validated Marathi and English EORTC QLQ-C30 and BR23 assessed QoL. Participants were selected using convenience sampling. Results: A total of 285 patients agreed to participate with a mean age of 54.2 ± 12.2 years and the mean score of Global Health Status (GHS)/QoL was 54.4 ± 19.6. Patients who received radiation had more pain ( p < 0.001), insomnia ( p < 0.001), and diarrhoea ( p = 0.005), whereas, those who received chemotherapy had higher scores in constipation ( p < 0.001) and loss of appetite ( p = 0.001). Co-morbidities were significantly associated with breast cancer-specific symptoms scales – upset by hair loss ( p = 0.025), arm symptoms ( p = 0.026), and breast symptoms ( p = 0.013). Conclusion: Education, occupation, hours of sleep, financial issues, and type of surgery were linked to the patient’s QoL. Therefore, these patients require additional attention and support services, including effective pain management and interventions to enhance sleep quality, to further enhance their QoL. Longitudinal studies incorporating detailed clinical and psychosocial variables are needed to understand the determinants of QoL.

  • Open Access

    Building Capacity in Institutional Operational Research in Low-Resource Settings: Protocol for an Implementation Research Study

    by Sana Ali, G V S Murthy, Kenneth L Bassett, Priya Reddy, Katie Judson, Suzanne Schwartz Gilbert, Abhilash Patra, Anirudh Gaurang Gudlavalleti, Debangana Mahapatra, Hira Pant, et al.

    Background: Operational research (OR) in eye care within resource-constrained settings helps develop context-specific solutions to local challenges. Building OR capacity among eye care personnel enables them to independently generate evidence that drives improvements in eye care delivery. Objective: This protocol describes the extended phase of the Institutional Operational Research Capacity Building (I-ORCB) program designed to train eye care professionals in the fundamentals and applications of OR. Methods: The I-ORCB program will be conducted in collaboration with Seva Canada and the Pragyaan Sustainable Health Outcomes Foundation over 3 years (2024‐2027). A total of 10 partner eye hospitals in India and Nepal will participate. The training is organized around 7 work packages covering quantitative and qualitative research methods, data management and analysis, community engagement, scientific writing, grant writing, and ethics. The program will be implemented in two sequential phases: (1) protocol development and ethics committee submission and (2) mentoring, data collection, data analysis, and manuscript preparation. Delivery will include workshops, ongoing mentorship, e-resources, and structured monitoring mechanisms. Evaluation will follow the Kirkpatrick model, and cost-effectiveness will be assessed through the change in knowledge among the participants brought about by the workshops. Results: This program is currently in the implementation phase. As of March 2025, a total of 10 teams have been enrolled in the I-ORCB program. Data collection for program evaluation began in June 2025 and is expected to continue until late 2026. Expected results include enhanced OR competencies among hospital teams, institutional strengthening for research, development of peer-reviewed manuscripts, and improved capacity to apply OR to service delivery challenges. The results of this program are expected to be published in 2027. Conclusions: The I-ORCB program applies a practical, learning-by-doing approach and is grounded in the Cooke framework for research capacity building. By integrating structured mentorship, institutional ownership, and flexible virtual learning components, the program is expected to strengthen OR culture in low- and middle-income countries and improve the delivery of eye care services in South Asia.

  • Open Access

    A Case of Breast Cancer Patient with Li–Fraumeni Syndrome: Psychosocial Implications and Literature Review

    by Rebecca Desouza, Shriniwas Subhas Kulkarni, Shona Nag, Atul Dongare, Aparna Dhar, Abhilash Patra, Hira B. Pant, Varun Agiwal, Nirupama A. Y., Sirshendu Chaudhuri, et al.

    Li–Fraumeni syndrome (LFS) is defined by the early emergence of tumors and is associated with mutations in the tumor suppression gene known as tumor protein 53 ( TP53). Information is scarce regarding the psychosocial challenges encountered by individuals with LFS and how it affects their treatment decisions. A 21-year-old woman developed multiple breast tumors over a period of nine years. Genetic testing identified a heterozygous missense substitution in exon 6 of the TP53 gene, specific variant chr17:7578190T>C c.659A>G (p.Tyr220Cys) listed in the dbSNP database. The report also highlights the psychosocial implications of the diagnosis at a young age and the patient’s reluctance to undergo the recommended bilateral mastectomy. The patient exhibited a significantly higher incidence of secondary tumors, underscoring the importance of comprehensive screening and timely diagnosis for managing LFS. This case highlights the challenges faced and the importance of emotional and psychological support after the diagnosis of hereditary syndromes, especially among young women.

  • Open Access

    Prevalence of BRCA mutation in breast and ovarian cancer among women in India: A systematic review and meta-analysis protocol

    by Abhilash Patra, Syeda Sana Ali, Ng Marina Devi, Amatullah Sana Qadeer, Sureshkumar Kamalakannan, Shona Nag, Shriniwas Subhash Kulkarni, Senthil Rajappa, Nisha Hariharan, Hira Ballabh Pant, et al.

    Purpose: We present a methodically devised protocol for conducting a systematic review and meta-analysis aimed at ascertaining the prevalence of BReast CAncer gene (BRCA) mutations in breast and ovarian cancer (BOC) among women in India. The review will include cross-sectional, cohort, case-series, and registry-based studies focusing on females clinically diagnosed with any stage of BOC, tested for BRCA germline mutation and undergone any form of treatment. Methods: A Cochrane literature search will be carried out to identify all the published and unpublished articles available in English from 2010 till date across various electronic databases including PubMed, Psych Info, SCI, Cochrane Central, Embase, Scopus, IND Med and Google Scholar. A step-by-step process will be followed to select all the relevant studies for final inclusion using Rayyan software. The selection process of the review will be reported based on Preferred Reporting Items for Systematic Review and Meta-analysis Protocols (PRISMA) checklist. The protocol has been registered in PROSPERO (ID: CRD42023463452). Joanna Briggs Institute Critical Appraisal Checklist will be used to evaluate the methodological quality of the included studies. The outcome measure will be the prevalence of BRCA1/2 gene mutation in this population. Meta-analysis will be performed to report the pooled prevalence along with 95% confidence interval. Discussion: The results of this review study will provide valuable insights for clinicians, and policy makers, enabling them to formulate guidelines that underscore the importance of screening for BRCA mutations in cases of BOC.


  • Open Access

    Burden of Financial Hardship Among Breast Cancer Survivors in Maharashtra, India

    by Abhilash Patra, Rebecca Desouza, Shona Nag, Hira B Pant, Varun Agiwal, Nirupama A Y, Yashaswini Kumar, Gvs Murthy

    Introduction: Improved breast cancer treatments have increased survival rates, but prolonged and costly therapies strain survivors financially. This study addresses the dearth of research on financial difficulties among breast cancer survivors (BCS) in India. Methods: A mixed -methods study was employed; we assessed financial hardship (FH) using the Comprehensive Score for Financial Toxicity -Functional Assessment of Chronic Illness Therapy (COSTFACIT), a validated 12 -item questionnaire. The minimum score represents FH (FH was categorized based on scores <27). Results: Out of 80 surveyed BCS, 60% experienced FH and had a median age of 48 years (40.5-56.5 years). Factors such as occupation, education, income, expenditures, insurance coverage, and impact on savings exhibited significant associations with FH. With only one-third having health insurance and 43.8% selffunding treatment, this research sheds light on the urgent need for targeted support and policies to alleviate the financial burdens faced by BCS in the Indian context. Conclusion: Financial hardship harms the mental and physical health of BCS. Collaborative efforts among policymakers, healthcare professionals, and insurers are crucial to establishing a compassionate healthcare system that addresses both immediate health and long-term financial concerns.


  • Open Access

    Efficacy and Satisfaction among HER2 Positive Breast Cancer Patients Undergoing Subcutaneous Injection of PHESGO along with Chemotherapy: A Case Series

    by Shona Nag, Anupama Mane, Madhuri Dhobale, Kavitha Varghese, Abhilash Patra, Hira B Pant, Varun Agiwal, Nirupama A Y, G V S Murthy

    Background: The prevalence of Human Epidermal Growth Factor Receptor 2 positive (HER2+) breast cancer (BC) in India ranged from 11% to 17%. A combination of intravenous (IV) pertuzumab, trastuzumab and docetaxel in HER2+ BC reported a significant increase in the overall survival rate. However, the time taken for infusion of these drugs is lengthy. PHESGO, a combination of these two drugs along with hyaluronidase is provided subcutaneously and the time taken is 5-8 minutes. Despite patient preference for PHESGO, its efficacy and satisfaction levels in the Indian context remain unexplored. This case series investigates the efficacy of PHESGO with chemotherapy and assesses the level of satisfaction reported by HER2+ BC patients. Methods: HER2+ BC patients were identified retrospectively from January 2022 to November 2023. Interviews during follow-ups assessed patient satisfaction. Efficacy was evaluated based on Positron Emission Tomography (PET) scans for metastatic/adjuvant settings and pathological complete response (pCR) rate for neoadjuvant cases. Results: In total 27 HER2+ BC patients received PHESGO treatment with a median age of 54.5 years. Patients who received PHESGO with chemotherapy in neoadjuvant and metastatic settings were 44.4% and 51.9% respectively. The median cycle of PHESGO with chemotherapy was 5. Neoadjuvant patients showed an 83.3% pCR rate, while 85.7% of metastatic patients reported partial response after three cycles. Among 25 patients, 92% were satisfied with subcutaneous administration of PHESGO. Conclusion: The findings support the potential of PHESGO as an effective and convenient treatment option for HER2+ BC patients. However, further research, including larger prospective studies and long-term follow-ups, is warranted to comprehensively evaluate the safety profile, quality of life, and comparative effectiveness of PHESGO versus intravenous administration.


  • Open Access

    Assessment of knowledge, attitude and practice (KAP) of parents/caregivers towards epilepsy in children – A cross- sectional observational study

    by Rahul Sinha, Dharmesh Soneji, V.V. Tewari, Sonali Singh, Priyabrata Kalikinkar Ojha, Abhilash Patra, Gautam Kamila, Sandeep Dhingra, Gurpreet Dhillon, Vandana Bansal, et al.


  • Mental Health Disorders Post-Stroke: A Scenario in India

    by Abhilash Patra, Sureshkumar Kamalakannan, Hira B. Pant, Varun Agiwal, Nirupama A.Y., Sirshendu Chaudhuri, Gudlavalleti S. Murthy

    Mental health disorders were reported in more than 33% of stroke survivors, which lead to increased comorbidities, delayed care, affect recovery, and impact physical and social functioning. Furthermore, it diminishes the quality of life and has impact on the well-being of both their families and caregivers. However, existing screening tools available for diagnosis of mental health disorders post-stroke detect many undiagnosed and underreported stroke survivors. Globally and in India, there has been a significant prevalence of post-stroke depression and anxiety. Pseudobulbar affect (PBA) ranged from 11% to 34%, worldwide. However, in India, only few case reports were reported for post-stroke psychosis, mania, and PBA. Although guidelines exist in developed countries for screening, referral, and rehabilitation of mental health disorders, there are lack of such resources in India. Also, the District Mental Health Program (DMHP) has received conflicting evaluations regarding its successes and shortcomings. Hence, this situation highlights the need for robust evidence-based strategies to develop effective screening, referral, and rehabilitation guidelines tailored to the Indian context. Also, by leveraging existing resources and collaborating with experts in the field, India can develop a comprehensive and effective approach to addressing post-stroke mental health disorders.

  • Open Access

    Prevalence of germline mutations in women with breast and/or ovarian cancer in a tertiary care center in Pune, India

    by Shriniwas Subhash Kulkarni, Shona Nag, Abhilash Patra, Hira Ballabh Pant, Varun Agiwal, A. Y. Nirupama, Sirshendu Chaudhuri, G. V. S. Murthy

    In India, the incidence of breast cancer accounted for 1,78,361 cases, whereas ovarian cancer accounts for 45,701 cases, according to Globocan Report 2020. These cancers are known to have a hereditary basis, and >10% of them are associated with pathogenic BRCA1 and BRCA2 mutations. The prevalence of BRCA1 and BRCA2 varies across various Indian studies and is reported to be 2.9–28%. However, gene mutations other than BRCA1 and BRCA2 which are shown to increase the risk of hereditary breast and ovarian cancer (HBOC) are underreported. Objectives: The objective of this study was to estimate the prevalence of deleterious germline mutations among women with breast and/or ovarian cancer. Material and Methods: A cross-sectional study was conducted in the department of oncology at a super specialty hospital. Patients were enrolled based on the current National Comprehensive Cancer Network guidelines for genetic risk and evaluation of HBOC. Demographic and clinical information was extracted from the electronic medical records of the hospitals from 2018 to 2021. Next-generation sequencing (NGS) was performed on the extracted DNA using a custom capture kit and classified based on the American College of Medical Genetics. Results: A total of 94 patients suspected of having HBOC were examined for deleterious germline mutations. The median age of the patient was 46 years (range: 38–57 years). Breast and ovarian cancer patients constituted 64.9% and 35.1%, respectively. The overall mutation detection rate was 25.5%. The positive mutation detection rate was 26.2% and 24.2% in breast and ovarian cancer, respectively, whereas the variant of uncertain significance rate was 18.03% and 24.2%, respectively. Among the pathogenic mutations, BRCA1 was the most common mutation in women with breast cancer (81.3%). In ovarian cancer, it was 50%. BRCA2 mutation was more prevalent in ovarian cancer (50%). Conclusion: Our study reports a higher prevalence of germline BRCA1 and BRCA2 mutations in breast and ovarian cancer as compared to other studies. Genetic testing can be offered to high-risk women regardless of family history. This will be useful during diagnosis and help physicians in planning subsequent treatment.


  • Clinical outcomes and quality of life after Total Knee Replacement (TKR) - A systematic review protocol

    by Lipika Nanda Nanda, Ambarish Dutta, Sarit Kumar Rout Rout, John Jebamalar, Naline Gandhi, Aiswarya Anilkumar, Pratik Ramesh Dhopte, Amatullah Sana Qadeer, Jennifer Rachel, Abhilash Patra

    Review question / Objective: Clinically, knee is the most common site of osteoarthritis (OA), followed by the hand and hip. The basic research question of our study: Is total knee replacement (TKR) associated with better clinical outcomes and quality of life among patients with OA knee aged 40 and above, not responding to non-surgical management, is? Based on this review question, the following objectives are proposed, 1. to refresh the evidence on clinical effectiveness of TKR and 2. to explore the determinants influencing its success. Population Patient aged >= 40 years with OA Knee of all Kellgren Lawrence grade. Intervention Total Knee Replacement (TKR) Comparator Pre-TKR Outcome Clinical effectiveness in terms of improvement in QoL.